Abstract:Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in people over age 65 in industrialized nations. The exudative AMD accounts for only 10% to 20% of AMD cases, but causes 80 to 90% of cases with severe vision loss related to AMD. The current intravitreal injection of anti-VEGF (vascular endothelial growth factor) therapies using Avastin or Lucentis has several unmet clinical needs, such as to minimize the frequency of injection, to decrease the systemic side effects, and to evaluate the effect of therapies. We propose to develop a drug delivery system that could perform sustained release of anti-VEGF drug by multifunctional drug-loaded microparticles (MPs). A modified double emulsion technique has firstly been used to fabricate biodegradable poly-lactic-co-glycolic acid (PLGA) MPs. The MPs could provide fluorescence, ultrasound, and OCT contrast simultaneously. Meanwhile, linear correlations has been observed between fluorescence intensity and MPs concentration, same as ultrasound intensity and MPs concentration. One of the anti-VEGF drugs (Avastin) has been conjugated to MPs to increase binding efficiency for target delivery. However, the modified double emulsion process is not suitable for encapsulating fragile protein drugs, such as Lucentis. The electrospray process has been introduced to overcome the limitations of the double emulsion process. Both monolayer MPs and double-layer MPs with core-shell structure are fabricated by single-axial and co-axial electrospray, respectively. To optimize the fabrication process, the effects of the applied voltage and the flow rate on the resulting and co-axial jet and the MPs size has been investigated. The results indicate that both the average size of MPs and the diameter of the co-axial jet increased as the flow rate increasing and decreased as the applied voltage increasing. A theoretical model using instability analysis has been developed to understand the process physics and predict the process outcome. Meanwhile, the biodegradation time of PLGA MPs as well as the bioavailability of Lucentis under single-axial electrospray is tested by enzyme-linked immunosorbent assay (Elisa). After the MPs fabrication and characterization, the inflammation experiment on intravitreal injection of MPs has been investigated by immunocytochemical analysis on in vivo chick model. CD45, Islet1, and Draq5 are used to label microglia, horizontal cells, and the nuclear DNA, respectively. TUNEL and CC3 are selected as cell death model to further investigate the cell apoptosis after injection. The results show that MP injection at a dose of 20??g and below does not cause inflammation under our experimental condition. However, significant microglia reactive as well as cell death (labeled by TUNEL) provided the evidence that MPs at a dose of 200??g and above induces significant retinal inflammation and cell death.

Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy

Novel fabrication of anti-VEGF drug ranibizumab loaded PLGA/PLA co-polymeric nanomicelles for long-acting intraocular delivery in the treatment of age-related macular degeneration therapy

Coaxial Electrospray of Ranibizumab-Loaded Microparticles for Sustained Release of Anti-VEGF Therapies.

Injectable Anti‐inflammatory Supramolecular Nanofiber Hydrogel to Promote Anti‐VEGF Therapy in Age‐Related Macular Degeneration Treatment

Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for Therapeutic Use in Age-Related Macular Degeneration Disease

Novel Therapeutic Perspectives for Wet Age-Related Macular Degeneration: RGD-modified Liposomes Loaded with 2-Deoxy-d-glucose As a Promising Nanomedicine

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Drug Loaded Multifunctional Microparticles for Anti-VEGF Therapy of Exudative Age-related Macular Degeneration

Emerging Co-Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal Neovascularization

C176-loaded and Phosphatidylserine-Modified Nanoparticles Treat Retinal Neovascularization by Promoting M2 Macrophage Polarization

Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based Microparticles as a Platform

Co-delivery of microRNA-150 and quercetin by lipid nanoparticles (LNPs) for the targeted treatment of age-related macular degeneration (AMD)

Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy

Intravenous anti-VEGF agents with RGD peptide-targeted core cross-linked star (CCS) polymers modified with indocyanine green for imaging and treatment of laser-induced choroidal neovascularization

Advanced nanomedicines for the treatment of age-related macular degeneration

Anti-Angiogenic Activity of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles for Potential Intravitreal Applications.

Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease

Nanotechnology for Age-Related Macular Degeneration

Topical Application of Cell-Penetrating Peptide Modified Anti-VEGF Drug Alleviated Choroidal Neovascularization in Mice

Targeted 8-arm PEG Nanosystems for Localization of Choroidal Neovascularization Macular Degeneration Model

Facile synthetic Photoluminescent Graphene Quantum dots encapsulated β-cyclodextrin drug carrier system for the management of macular degeneration: Detailed analytical and biological investigations